January 16, 2025 11:20 AM ESTUpdated 04:13 PM
Pharma
Law

No­var­tis en­ters fight against HHS for deny­ing its 340B re­bate mod­el

Alexis Kramer

Pharma Editor

No­var­tis is the lat­est drug­mak­er to sue the gov­ern­ment for al­leged­ly re­ject­ing its pro­posed mod­el to dis­trib­ute fed­er­al drug dis­counts.

The

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Broad In­sti­tute pa­per of­fers po­ten­tial new frame­work for treat­ing Hunt­ing­ton’s dis­ease

FDA re­jects Atara's cell ther­a­py for rare trans­plant com­pli­ca­tion, stock craters

Boehringer's schiz­o­phre­nia as­set fails Phase 3; GSK buys organoid biotech

Vac­cine patch start­up col­lects an ad­di­tion­al $16M to Se­ries A

A mixed year for deals and dol­lars left biotech ex­ecs hun­gry for a bet­ter 2025

HHS blasts Boehringer's drug price case, re­veals new de­tails on Jar­diance talks

A service from the Financial Times